A simple neck scan could detect men at high risk of heart failure

A simple neck scan can identify men with double the risk of heart failure, according to research led by University College ...
Medscape

Emergency Department Visits for Altered Mental Status Often Receive Nonspecific Symptom Diagnoses

Patients visiting US emergency departments for altered mental status commonly receive nonspecific symptom diagnoses, ...
Zacks Investment Research on MSN

BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi

Bristol Myers Squibb BMY obtained the European Commission’s (“EC”) approval for a label expansion of Breyanzi (lisocabtagene ...
Medscape

Current Risk Scores Miss Nearly Half of First Heart Attacks

Nearly half of adults with a first myocardial infarction show low or borderline risk on current risk estimators. Most develop ...
Pharmabiz

Bayer’s asundexian meets primary efficacy and safety endpoints in landmark phase III OCEANIC-STROKE study in secondary stroke prevention

Bayer’s asundexian meets primary efficacy and safety endpoints in landmark phase III OCEANIC-STROKE study in secondary stroke prevention: Berlin Tuesday, November 25, 2025, 11:0 ...

BAYRYs Cardiovascular Drug Hits Goals in Late-Stage Study

Bayer's asundexian hits key goals in the OCEANIC-STROKE study, showing reduced ischemic stroke risk without added major ...
TCTMD

Asundexian Reduces Recurrent Stroke Without Bleeding Risk: OCEANIC-STROKE

Asundexian (Bayer) significantly reduces the risk of ischemic stroke compared with placebo, without increasing the risk of ...
Clinical Trials Arena on MSN

Bayer reports positive results from Phase III OCEANIC-STROKE study

The trial met its main safety and efficacy endpoints in participants who experienced a non-cardioembolic ischemic stroke.
Emirates News Agency

Bayer’s Asundexian meets main goals in Phase III stroke trial

Bayer Sunday announced positive topline results from the global Phase III study OCEANIC-STROKE, with its investigational, once daily, oral FXIa inhibitor asundexian.The study met its primary efficacy ...

Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention

Bayer today announced positive topline results from the global Phase III study OCEANIC-STROKE, with its investigational, once daily, oral FXIa inhibitor asundexian. The study met its primary efficacy ...